middle.news
How Argent BioPharma’s AusCann Deal Reshape Could Accelerate CannEpil® Progress
8:26am on Friday 30th of January, 2026 AEDT
•
Healthcare
Read Story
How Argent BioPharma’s AusCann Deal Reshape Could Accelerate CannEpil® Progress
8:26am on Friday 30th of January, 2026 AEDT
Key Points
Restructured acquisition of 48% stake in CannPal Animal Therapeutics
Option secured to acquire Neuvis® drug-delivery platform IP
A$11 million convertible securities financing facility established
Operating cash outflows of A$1.553 million for December quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RGT
OPEN ARTICLE